Study Evaluating Safety & Immunogenicity of rLP2086 Vaccine in Adolescents
NCT ID: NCT00387725
Last Updated: 2014-11-21
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
127 participants
INTERVENTIONAL
2006-11-30
2008-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A
20ug Experimental
rLP2086
Vaccine administered at 0, 1, and 6 months
Group 2
60ug Experimental
rLP2086
Vaccine administered at 0, 1, and 6 months
Group 3
200ug Experimental
rLP2086
Vaccine administered at 0, 1, and 6 months
Group 4
Active comparator
rLP2086
Vaccine administered at 0, 1, and 6 months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
rLP2086
Vaccine administered at 0, 1, and 6 months
rLP2086
Vaccine administered at 0, 1, and 6 months
rLP2086
Vaccine administered at 0, 1, and 6 months
rLP2086
Vaccine administered at 0, 1, and 6 months
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Healthy male or female subjects
* Negative urine pregnancy test for female subjects
Exclusion Criteria
* Prior meningococcal disease
8 Years
14 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sydney Children's Hospital
Randwick, New South Wales, Australia
The Children's Hospital at Westmead
Westmead, New South Wales, Australia
Royal Children's Hospital
Herston, Queensland, Australia
Princess Margaret Hospital for Children
Subiaco, Western Australia, Australia
Sir Albert Sakzewski Virus Research Centre (SASVRC)
Herston, , Australia
Women's & Children's Hospital
North Adelaide, , Australia
The Telethon Institute for Child Health Research
Subiaco, , Australia
National Centre for Immunisation
Westmead, , Australia
Department of Paediatrics and Child Health
Woden, , Australia
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B1971006
Identifier Type: OTHER
Identifier Source: secondary_id
6108A1-501
Identifier Type: -
Identifier Source: org_study_id